DEF 14A: TG Therapeutics Seeks Stockholder Approval for Certificate of Incorporation and Incentive Plan Amendments

TG Therapeutics is asking stockholders to approve amendments to its Certificate of Incorporation to increase authorized common stock and to its 2022 Incentive Plan to remove the full-value awards limit at the upcoming Annual Meeting on June 14, 2024.

Summary

• TG Therapeutics is holding its Annual Meeting of Stockholders virtually on June 14, 2024.
• Stockholders will vote on several proposals, including the election of six directors, ratification of KPMG LLP as the independent accounting firm, and approval of executive compensation.
• A key proposal involves amending the Certificate of Incorporation to increase the authorized shares of common stock from 175,000,000 to 190,000,000.
• Another proposal seeks to amend the 2022 Incentive Plan to remove the full-value awards limit, maintaining the overall share limit at 17,000,000 shares.
• As of April 17, 2024, there were 154,542,945 shares of common stock outstanding.
• Directors and executive officers owned approximately 10.5% of the outstanding common stock as of the record date.

Sentiment

Score: 7

Explanation: The document is neutral in tone, presenting standard corporate governance matters for stockholder approval. The proposals are generally positive for the company's flexibility and long-term planning.

Positives

• The proposed increase in authorized shares provides flexibility for future acquisitions, financings, and equity awards.
• Removing the full-value awards limit in the 2022 Incentive Plan allows for more flexible equity compensation strategies.
• The company maintains sound corporate governance practices, including a clawback policy and prohibitions on repricing stock options without stockholder approval.
• The company has a compensation consultant to advise on executive and director compensation.

Negatives

• The proposal to increase authorized shares could have an anti-takeover effect.
• At the 2023 Annual Meeting of Stockholders, approximately 46.7% of the shares represented and entitled to vote at the annual meeting voted to approve the compensation of the Company's named executive officers, as discussed and disclosed in the 2023 Proxy Statement, which was below desired levels.

Risks

• Failure to approve the amendment to the 2022 Incentive Plan could limit the company's ability to attract and retain talent.
• The increased authorized shares could be used to dilute existing stockholders' voting power.
• The company's compensation programs are subject to tax and accounting considerations, including Sections 409A, 280G, and 162(m) of the Code.

Future Outlook

The company aims to ensure shares are available for acquisitions, partnering, financings, potential share purchases under existing licensing agreements, for issuance in connection with grants of equity awards under our equity incentive plans, and other corporate purposes.

Management Comments

• Michael S. Weiss, Chairman, Chief Executive Officer and President, encourages stockholders to specify their voting preferences.
• The Board of Directors believes that an increase in the number of shares authorized for issuance is in the Company's best interests.

Industry Context

The document references the Nasdaq listing rules related to board diversity and mentions peer group companies in the biotechnology, life sciences, and pharmaceutical sectors for compensation benchmarking.

Comparison to Industry Standards

• The document mentions benchmarking executive compensation against a peer group of 18 publicly traded companies in the biotechnology, life sciences, and pharmaceutical sectors.
• The peer group includes companies such as Acadia Pharmaceuticals, Deciphera Pharmaceuticals, Mirati Therapeutics, and others with comparable market capitalization and revenue.
• The company's compensation consultant analyzes the NEO and non-executive director compensation of the peer group to evaluate the company's compensation components and practices.

Related Party Transactions

• The company has an Office Agreement and a Shared Services Agreement with Fortress Biotech, Inc., where Michael S. Weiss also serves as a director and Executive Vice Chairman.
• The company has a Global Collaboration Agreement with Checkpoint Therapeutics, Inc., a subsidiary of Fortress Biotech, Inc., where Michael S. Weiss also serves as Chairman of the Board of Directors.

Stakeholder Impact

• Approval of the proposals could impact shareholders by providing the company with greater flexibility for future financings and equity awards.
• Employees may benefit from the amended 2022 Incentive Plan, which could enhance the company's ability to attract and retain talent.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 14, 2024.
• The company will implement the approved amendments to the Certificate of Incorporation and the 2022 Incentive Plan.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Certificate of Incorporation, Incentive Plan, Executive Compensation, Board of Directors, KPMG LLP, Common Stock, Equity Awards, TG Therapeutics